ArticleJCI insight2018
Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation.
Article in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Lymphatic system in the liver: a new frontier in liver physiology and oncology.Medical molecular morphology · 2026Review
- Cutaneous lymphatics and skin diseases: mechanisms, imaging modalities, and future therapeutic strategies.Frontiers in physiology · 2026Review
- A Novel Mutation in Exon 10 of the NOTCH3 Gene in Human Cerebral Microvascular Endothelial Cells Induces CADASIL-Like Pathology and the Therapeutic Effect of Edaravone Dexborneol on Hereditary and Non-hereditary Cerebral Small Vessel Disease.Neurochemical research · 2025Article
- Dysregulated lymphatic remodeling promotes immunopathology during non-healing cutaneous leishmaniasis.bioRxiv : the preprint server for biology · 2025Article
- An Update on the Role of Lymphatic Function in Skin Inflammatory Disorders: A Scoping Review.Cureus · 2025Review
- Tissue-resident macrophages specifically express Lactotransferrin and Vegfc during ear pinna regeneration in spiny mice.Developmental cell · 2024Article
- The role of dermal fibroblasts in autoimmune skin diseases.Frontiers in immunology · 2024Review
- Novel biomarker discovery through comprehensive proteomic analysis of lupus mouse serum.Journal of autoimmunity · 2024Article
- Signaling mechanisms underlying lymphatic vessel dysfunction in skin aging and possible anti-aging strategies.Biogerontology · 2023Review
- Recombinant VEGF-C (Cys156Ser) improves mesenteric lymphatic drainage and gut immune surveillance in experimental cirrhosis.JHEP reports : innovation in hepatology · 2023Article
- Promotion of Lymphangiogenesis by Targeted Delivery of VEGF-C Improves Diabetic Wound Healing.Cells · 2023Article
- Article
- Hepatic lymphatic vascular system in health and disease.Journal of hepatology · 2022Review
- Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.The British journal of dermatology · 2022Review
- Biochemical and mechanical signals in the lymphatic vasculature.Cellular and molecular life sciences : CMLS · 2021Review
- Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway.Nature communications · 2021Article
- The lymphatic system in alcohol-associated liver disease.Clinical and molecular hepatology · 2020Review
- The Role of Lymphatic Vascular Function in Metabolic Disorders.Frontiers in physiology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEGF-C is an important mediator of lymphangiogenesis and has been shown to alleviate chronic inflammation in a variety of disease models. In this study, we investigated whether targeted delivery of VEGF-C to sites of inflammation and site-specific activation of lymphatic vessels would represent a clinically feasible strategy for treating chronic skin inflammation. To this end, we generated a fusion protein consisting of human VEGF-C fused to the F8 antibody (F8-VEGF-C), which is specific for the alternatively spliced, angiogenesis-marking extradomain A (EDA) of fibronectin. In two mouse models of psoriasis-like skin inflammation, mediated by transgenic VEGF-A overexpression or repeated application of imiquimod, intravenous treatment with F8-VEGF-C but not with untargeted VEGF-C significantly reduced ear skin edema and was as effective as the clinically used TNF-α receptor-Fc fusion protein (TNFR-Fc). Treatment with F8-VEGF-C led to a marked expansion of lymphatic vessels in the inflamed skin and significantly improved lymphatic drainage function. At the same time, treatment with F8-VEGF-C significantly reduced leukocyte numbers, including CD4+ and γδ T cells. In sum, our results reveal that targeted delivery of VEGF-C and site-specific induction of lymphatic vessels represent a potentially new and promising approach for the treatment of chronic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.